MannKind reported $20.57M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Adma Biologics USD 54.76M 544K Jun/2025
Dynavax Technologies USD 14.04M 13.5M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Halozyme Therapeutics USD 64.12M 15.72M Jun/2025
Insmed USD 29.34M 8.06M Jun/2025
MacroGenics USD 49.7M 44.21M Jun/2025
MannKind USD 20.57M 3.55M Jun/2025
Merck USD 2.82B 53M Jun/2025
Novo Nordisk DKK 12.89B 1.58B Mar/2025
Pfizer USD 4.99B 2.4B Jun/2025
Sanofi EUR 2.99B 103M Jun/2025
Xencor 61.66M 50.95M Jun/2025